Treatment-Related Acute Myeloid Leukemia (DBCOND0103034)

Identifiers

Synonyms

Therapy-Related Acute Myeloid Leukemia

Associated Data

Indicated Drugs and Targets

Drug	Description	Targets
Cytarabine	A pyrimidine nucleoside analogue used to treat acute non-lymphocytic leukemia, lymphocytic leukemia, and the blast phase of chronic myelocytic leukemia.	DNA polymerase betatarget Cytidine deaminaseenzyme Solute carrier family 22 member 4transporter ATP-binding cassette sub-family C member 10transporter Equilibrative nucleoside transporter 1transporter DNAtarget Cytochrome P450 3A4enzyme Deoxycytidine kinaseenzyme 5'-nucleotidaseenzyme Deoxycytidylate deaminaseenzyme DNA polymerase catalytic subunittarget
Daunorubicin	An anthracycline aminoglycoside used to induce remission of nonlymphocytic leukemia and acute lymphocytic leukemia.	DNAtarget Cytochrome P450 3A5enzyme NADPH--cytochrome P450 reductaseenzyme ATP-dependent translocase ABCB1transporter Multidrug resistance-associated protein 1transporter ATP-binding cassette sub-family C member 6transporter ATP-binding cassette sub-family C member 10transporter Broad substrate specificity ATP-binding cassette transporter ABCG2transporter DNA topoisomerase 2-alphatarget DNA topoisomerase 2-betatarget Cytochrome P450 1B1enzyme Cytochrome P450 3A4enzyme Aldo-keto reductase family 1 member B1enzyme Carbonyl reductase [NADPH] 1enzyme Carbonyl reductase [NADPH] 3enzyme

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT05292664	Venetoclax Basket Trial for High Risk Hematologic Malignancies	Asparaginase Erwinia chrysanthemi Azacitidine Calaspargase pegol Calcium Cortisone Cytarabine Dexamethasone Dexrazoxane Doxorubicin Hydrocortisone Hydrocortisone phosphate Hydrocortisone succinate Leucovorin Methotrexate Venetoclax Vincristine	treatment	1	recruiting
NCT03365661	QUILT-3.034: Non-Myeloablative TCRa/b Deplete Haplo HSCT With Post ALT-803 for AML	Nogapendekin alfa	treatment	2	withdrawn
NCT06143839	VYxeoS Liposomal Italian Observational Study iN the Real Practice	Cytarabine Daunorubicin	Not Available	Not Available	recruiting
NCT04062266	AZA + Venetoclax as Maintenance Therapy in Patients With AML in Remission	Azacitidine Venetoclax	treatment	2	recruiting
NCT04128501	Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting	Azacitidine Venetoclax	treatment	2	recruiting
NCT02658487	Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia	Cytarabine Vosaroxin	treatment	2	active_not_recruiting
NCT04518345	TP-0903 for the Treatment of FLT3 Mutated Acute Myeloid Leukemia	Azacitidine Dubermatinib	treatment	0	completed
NCT01823198	Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies	Aldesleukin Busulfan Fludarabine Natural Killer Cell	treatment	1 / 2	completed
NCT01619761	NK Cells in Cord Blood Transplantation	Cyclophosphamide Fludarabine Lenalidomide Mechlorethamine Mycophenolate mofetil Natural Killer Cell Rituximab Tacrolimus	treatment	1	unknown_status
NCT02323607	Pacritinib and Chemotherapy in Treating Patients With Acute Myeloid Leukemia and FLT3 Mutations	Cytarabine Daunorubicin Decitabine Pacritinib	treatment	1	completed
NCT01253070	Sorafenib Tosylate and Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia	Cytarabine Daunorubicin Sorafenib	treatment	2	completed
NCT01904136	Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia	Cyclophosphamide Fludarabine Mechlorethamine Mycophenolate mofetil Natural Killer Cell Tacrolimus	treatment	1 / 2	completed
NCT04269213	CPX-351 for the Treatment of Secondary Acute Myeloid Leukemia in Patients Younger Than 60 Years Old	Cytarabine Daunorubicin	treatment	2	recruiting
NCT03226418	Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia	Azacitidine Cytarabine Daunorubicin Decitabine Glasdegib Idarubicin Venetoclax	treatment	2	active_not_recruiting
NCT02381548	Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia	Adavosertib Belinostat	treatment	1	terminated
NCT01420926	Decitabine With or Without Bortezomib in Treating Older Patients With Acute Myeloid Leukemia	Bortezomib Bortezomib D-mannitol Decitabine	treatment	2	completed
NCT03009240	Pevonedistat and Decitabine in Treating Patients With High Risk Acute Myeloid Leukemia	Decitabine Pevonedistat	treatment	1	active_not_recruiting
NCT01640301	Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated With Donor Stem Cell Transplant	Aldesleukin Cyclophosphamide Fludarabine	treatment	1 / 2	terminated
NCT03330821	Pevonedistat, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia	Cytarabine Idarubicin Pevonedistat	treatment	1 / 2	active_not_recruiting
NCT03272633	Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies	No drug interventions	treatment	0	terminated
NCT03602898	Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation	Aloe vera leaf Ascorbic acid Busulfan Cyclophosphamide Cyclosporine Fludarabine Glycerin Methopterin Methotrexate Nicotinamide Tacrolimus Vitamin A	treatment	2	withdrawn
NCT01238211	Combination Chemotherapy and Dasatinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia	Cytarabine Dasatinib Daunorubicin	treatment	2	completed
NCT01130506	Decitabine, Vorinostat, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome	Cytarabine Decitabine Vorinostat	treatment	1	completed
NCT03526926	A Post-Marketing Observational Study of VYXEOS™	Cytarabine Daunorubicin	Not Available	Not Available	completed
NCT02397720	Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia	Azacitidine Ipilimumab Nivolumab	treatment	2	completed
NCT01760655	Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies	1,4-Butanediol Busulfan Cyclophosphamide Fludarabine Mycophenolate mofetil Tacrolimus Therapeutic allogeneic lymphocytes	treatment	2	completed